Zi X - Search Results

1

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Lu Y, et al. Among authors: zi x. J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7. doi: 10.1093/jnci/93.24.1852. J Natl Cancer Inst. 2001. PMID: 11752009

2

Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.

Zi X, Zhang J, Agarwal R, Pollak M. Zi X, et al. Cancer Res. 2000 Oct 15;60(20):5617-20. Cancer Res. 2000. PMID: 11059749

3

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.

Lu Y, Zi X, Pollak M. Lu Y, et al. Among authors: zi x. Int J Cancer. 2004 Jan 20;108(3):334-41. doi: 10.1002/ijc.11445. Int J Cancer. 2004. PMID: 14648698 Free article.

4

Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.

Lu Y, Zi X, Zhao Y, Pollak M. Lu Y, et al. Among authors: zi x. Biochem Biophys Res Commun. 2004 Jan 16;313(3):709-15. doi: 10.1016/j.bbrc.2003.12.007. Biochem Biophys Res Commun. 2004. PMID: 14697248

5

Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis.

Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Liu B, et al. Among authors: zi x. Oncogene. 2007 Mar 15;26(12):1811-9. doi: 10.1038/sj.onc.1209977. Epub 2006 Sep 18. Oncogene. 2007. PMID: 16983336

6

High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.

Liu Z, Yokoyama NN, Blair CA, Li X, Avizonis D, Wu XR, Uchio E, Youssef R, McClelland M, Pollak M, Zi X. Liu Z, et al. Among authors: zi x. Mol Cancer Ther. 2016 Mar;15(3):430-8. doi: 10.1158/1535-7163.MCT-15-0714-T. Epub 2016 Feb 26. Mol Cancer Ther. 2016. PMID: 26921394 Free PMC article.

7

A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.

Zi X, Grasso AW, Kung HJ, Agarwal R. Zi X, et al. Cancer Res. 1998 May 1;58(9):1920-9. Cancer Res. 1998. PMID: 9581834

8

Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling.

Guo Y, Xie J, Rubin E, Tang YX, Lin F, Zi X, Hoang BH. Guo Y, et al. Among authors: zi x. Cancer Res. 2008 May 1;68(9):3350-60. doi: 10.1158/0008-5472.CAN-07-3220. Cancer Res. 2008. PMID: 18451162 Free PMC article.

9

Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma.

Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. Rubin EM, et al. Among authors: zi x. Mol Cancer Ther. 2010 Mar;9(3):731-41. doi: 10.1158/1535-7163.MCT-09-0147. Epub 2010 Mar 2. Mol Cancer Ther. 2010. PMID: 20197388 Free PMC article.

10

Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness.

Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF, Hoang BH. Zi X, et al. Cancer Res. 2005 Nov 1;65(21):9762-70. doi: 10.1158/0008-5472.CAN-05-0103. Cancer Res. 2005. PMID: 16266997

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

308 results

Search Page